Aicardi-Goutieres syndrome Trials in Disease

Study on the Safety of Censavudine (TPN-101) for Patients with Aicardi-Goutières Syndrome

This clinical trial is investigating censavudine, also known as TPN-101, as a potential treatment for Aicardi-Goutières Syndrome. The medication is administered as a powder mixed with water to create an oral solution that patients drink.

Who can participate:

The trial is open to patients across a wide age range, divided into four groups: adults aged 18 years and older, adolescents aged 12 to 17, children aged 5 to 11, and younger children aged 1 to under 5 years who weigh at least 10 kilograms. Both males and females can participate.

To be eligible, participants must have a confirmed genetic diagnosis of Aicardi-Goutières Syndrome based on specific gene mutations. They must also have an elevated interferon score in their blood, which is a measure of immune system activity that is typically higher than normal in people with this condition.

Participants should show symptoms consistent with the syndrome, which may include early developmental delays, movement difficulties, muscle stiffness, small head size, calcium deposits in the brain, brain tissue changes, brain shrinkage, or other early signs like irritability, feeding and sleeping problems, unexplained fevers, and skin issues.

Women of childbearing age must agree to use effective birth control during the study and for three months afterward, and cannot be pregnant or breastfeeding. Male participants with partners who can become pregnant must use condoms and ensure their partners use effective birth control during the same period.

Who cannot participate:

Patients with conditions other than Aicardi-Goutières Syndrome are not eligible. Those who fall outside the specified age ranges or who cannot follow the study procedures are also excluded. Pregnant or breastfeeding women cannot participate, nor can those taking certain medications that might interfere with the study drug. Patients who have recently participated in another clinical trial may also be ineligible.

What the trial aims to learn:

The primary goal of this trial is to evaluate whether TPN-101 is safe for patients with Aicardi-Goutières Syndrome and whether it can reduce the interferon score, which reflects inflammation in the body. The trial will last up to 48 weeks, during which participants will receive either TPN-101 or a placebo.

Throughout the study, researchers will monitor participants closely for any side effects. They will measure drug levels in both blood and cerebrospinal fluid (the fluid surrounding the brain and spinal cord) and examine various biomarkers to understand how the medication affects the body. Regular assessments will include blood tests, brain scans using MRI to evaluate changes in brain structure and function, and evaluations of clinical and functional status.

The trial follows a structured timeline: after an initial screening period of approximately 8 weeks where blood samples are collected multiple times to confirm interferon levels, participants enter a treatment phase lasting up to 48 weeks. Regular assessments continue throughout, with a final evaluation at the end of treatment and potential follow-up visits to monitor long-term effects.

TPN-101 works as an immunomodulatory agent, meaning it is designed to adjust the immune system's activity. At the molecular level, it is believed to work by reducing the overproduction of interferon, which is a key factor contributing to symptoms in Aicardi-Goutières Syndrome. The medication is still in the investigational stage, and this research aims to gather important information about its potential benefits and risks for treating this challenging condition.